Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Blonanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Blonanserin SCHEMBL29379647 | 1.00 | DRD2 (1.00) | DRD2HTR2ACYP1A2CYP3A4POLB | |
| SCHEMBL7334897 | 1.00 | DRD2 (1.00) | DRD2HTR2ACYP1A2CYP3A4POLB | |
| Blonanserin SCHEMBL28331931 | 0.99 | DRD2 (0.98) | DRD2HTR2ACYP1A2CYP3A4POLB | |
| Blonanserin SCHEMBL28204389 | 0.99 | DRD2 (0.98) | DRD2HTR2ACYP1A2CYP3A4POLB | |
| SCHEMBL7333157 | 0.97 | DRD2 (0.93) | DRD2HTR2ACYP1A2CYP3A4POLB | |
| SCHEMBL7326283 | 0.91 | DRD2 (0.84) | DRD2HTR2ACYP1A2CYP3A4POLB | |
| SCHEMBL7325078 | 0.89 | HTR2A (0.80) | DRD2HTR2ACYP1A2CYP3A4KDM4E | |
| SCHEMBL7335126 | 0.89 | DRD2 (0.80) | DRD2HTR2APOLBKDM4EALDH1A1 | |
| SCHEMBL7333811 | 0.88 | DRD2 (0.79) | DRD2HTR2APOLBKDM4EALDH1A1 | |
| SCHEMBL7328292 | 0.88 | HTR2A (0.79) | DRD2HTR2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3833 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121570440-A | High-water permeability and high-adhesion pressure-sensitive adhesive patch matrix and preparation method and application thereof | 沈阳药科大学 | 2026-02-27 | — | — | CN | claimed |
| EP-4699659-A2 | CRYSTALLINE FORMS OF EVENAMIDE | Newron Pharmaceuticals S.p.A. (IT) | 2026-02-25 | — | — | EP | claimed |
| US-12544360-B2 | Pharmaceutical composition for preventing or treating coronavirus disease-19 | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-02-10 | — | — | US | claimed |
| EP-4615820-B1 | CRYSTALLINE FORMS OF EVENAMIDE | NEWRON PHARM SPA (IT) | 2026-02-04 | — | — | EP | claimed |
| EP-4674482-A2 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-01-07 | — | — | EP | claimed |
| US-20260000641-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (IMDAI) | TERRAN BIOSCIENCES INC (US) | 2026-01-01 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615820-A1 | CRYSTALLINE FORMS OF EVENAMIDE | Newron Pharmaceuticals S.p.A. (IT) | 2025-09-17 | — | — | EP | claimed |
| CN-120114384-A | Blonanserin water-based solution preparation and preparation method thereof | 苏州康纯医药科技有限公司 | 2025-06-10 | — | — | CN | claimed |
| WO-2003066039-A1 | COMBINATION THERAPY FOR TREATMENT OF SCHIZOPHRENIA | ABBOTT LABORATORIES (US) | 2003-08-14 | — | — | WO | claimed |
| US-20030109546-A1 | Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-12 | — | — | US | claimed |
| WO-2002087590-A1 | TREATMENT OF PSYCHOTIC DISORDERS COMPRISING CO-THERAPY WITH ANTICONVULSANT DERIVATIVES AND ATYPICAL ANTIPSYCHOTICS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| US-20020156067-A1 | New drug combinations | PHARMACIA & UPJOHN COMPANY | 2002-10-24 | — | — | US | claimed |
| EP-1238676-A1 | Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis | Pfizer Products Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| US-20020123490-A1 | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis | PFIZER INC. | 2002-09-05 | — | — | US | claimed |
| WO-2002053140-A2 | NEW DRUG COMBINATIONS OF NOREPINEHRINE REUPTAKE INHIBITORS AND NEUROLEPTIC AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-07-11 | — | — | WO | claimed |
| EP-0385237-B1 | 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same | DAINIPPON PHARMACEUTICAL CO (JP) | 1994-06-29 | — | — | EP | claimed |
| US-5021421-A | Psychotropic agents | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1991-06-04 | — | — | US | claimed |
| EP-0385237-A2 | 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1990-09-05 | — | — | EP | claimed |